Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …

Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and
limited treatment options. Here we provide a comprehensive census of the bone marrow …

T cell immunoglobulin and mucin-containing molecule 3 (TIM-3), first identified as a
molecule expressed on interferon-γ producing T cells, is emerging as an important immune …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …

Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic
responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this …

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic
cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …